Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Jahr

2016

Autoren

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Ziemssen T, Compston DA; CARE-MS II Investigators.

Verlag

Neurology. 2016 Nov 8;87(19):1985-1992.

Link

https://doi.org/10.1212%2FWNL.0000000000003319

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study

Eculizumab Use in Neuromyelitis Optica Spectrum Disorders

Higher effect sizes for the detection of accelerated brain volume loss and disability progression in multiple sclerosis using deep-learning